Early transfusion of convalescent plasma improves the clinical outcome in severe SARS-CoV2 infection

Fodor, E.; Muller, V.; Ivanyi, Z.; Berki, T.; Kuten, O. P.; Ambrus, M.; Sarkany, A.; Skazel, A.; Madar, A.; Kardos, D.; Kemenesi, G.; Foldes, F.; Nagy, S.; Matusovits, A.; Nacsa, J.; Tordai, A.; Jakab, F.; Lacza, Z.

Plasma harvested from convalescent COVID-19 patients (CCP) has been applied as first-line therapy in the early phase of the SARS-CoV2 pandemic through clinical studies using various protocols. We present data from a cohort of 267 hospitalized, severe COVID-19 patients who received CCP. No transfusion-related complications were reported, indicating the overall safety of CCP therapy. Patients who eventually died from COVID-19 received CCP significantly later (3.95 versus 5.22 days after hospital admission) and had higher interleukin 6 (IL-6) levels (28.9 pg/ml versus 102.5 pg/ml) than those who survived. In addition, CCP-transfusion caused a significant reduction in the overall inflammatory status of the patients regardless of the severity of disease or outcome, as evidenced by decreasing C-reactive protein, IL6 and ferritin levels. We conclude that, CCP-transfusion is a safe and effective supplementary treatment modality for hospitalized COVID-19 patients characterized by better expected outcome if applied as early as possible. We also observed that, IL-6 may be a suitable laboratory parameter for patient selection and monitoring of CCP therapy effectiveness.